Is there any correlation between binding and functional effects at the translocator protein (TSPO) (18 kDa)?

Current Molecular Medicine

Volumn 12, Issue 4, 2012, Pages 387-397

  Scarf, A M ^a   Auman, K M ^a   Kassiou, M ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Apoptosis; Multiple binding sites; Neuroprotection; Radioligand binding; Steroidogenesis; Translocator protein (TSPO)

Indexed keywords

4' CHLORODIAZEPAM; CENTRAL NERVOUS SYSTEM AGENTS; DAA 1106; DPA 713; EMAPUNIL; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PBR 06; PBR 111; PBR 28; PROTEIN; TRANSLOCATOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CORRELATION ANALYSIS; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; STEROIDOGENESIS;

EID: 84860312483     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011207040387     Document Type: Article

References (110)

1. Scarf AM, Ittner LM, Kassiou M. The translocator protein (18 kDa): Central nervous system disease and drug design. J Med Chem 2009; 52: 581-92.
2. Choi J, Ifuku M, Noda M, Guilarte TR. Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state. Glia 2011; 59: 219-30.
3. Messmer K, Reynolds GP. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. Neurosci Lett 1998; 241: 53-6.
4. Gulyás B, Makkai B, Kása P, et al. A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and agematched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochem Int 2009; 54: 28-36.
5. Banati R, Newcombe J, Gunn R, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000; 123: 2321-37.
6. Luus C, Hanani R, Reynolds A, Kassiou M. The development of PET radioligands for imaging the translocator protein (18 kDa): What have we learned? J Labelled Comp Rad 2010; 53: 501-510.
7. Versijpt J, Dumont F, Van Laere K, et al. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. Eur Neurol 2003; 50: 39-47.
8. Pavese N, Gerhard A, Tai YF, et al. Microglial activation correlates with severity in Huntington disease: A clinical and PET study. Neurology 2006; 66: 1638-43.
9. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006; 21: 404-12.
10. 11C]PK11195 challengers. Eur J Nucl Med Mol Imaging 2008; 35(12): 2304-19.
11. Dolle F, Luus C, Reynolds A, Kassiou M. Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography. Curr Med Chem 2009; 16: 2899-923.
12. Scarf AM, Kassiou M. The translocator protein. J Nucl Med 2011; 52: 677-80.
13. Chelli B, Pini S, Abelli M, et al. Platelet 18 kDa translocator protein density is reduced in depressed patients with adult separation anxiety. Eur Neuropsychopharmacol 2008; 18: 249-54.
14. Ritsner M, Modai I, Gibel A, et al. Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patients. J Psychiatr Res 2003; 37: 549-56.
15. Lacapere J-J, Papadopoulos V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids 2003; 68: 569-85.
16. McEnery M, Snowman A, Trifiletti R, Snyder S. Isolation of the mitochondrial benzodiazepine receptor: Association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc Natl Acad Sci USA 1992; 89: 3170-4.
17. Joseph-Liauzun E, Farges R, Delmas P, Ferrara P, Loison G. The Mr 18,000 subunit of the peripheral-type benzodiazepine receptor exhibits both benzodiazepine and isoquinoline carboxamide binding sites in the absence of the voltage-dependent anion channel or of the adenine nucleotide carrier. J Biol Chem 1997; 272: 28102-28106.
18. Galiegue S, Jbilo O, Combes T, et al. Cloning and characterization of PRAX-1. A new protein that specifically interacts with the peripheral benzodiazepine receptor. J Biol Chem 1999; 274: 2938-2952.
19. Hauet T, Yao Z-X, Bose HS, et al. Peripheral-type benzodiazepine receptor-mediated action of steroidogenic acute regulatory protein on cholesterol entry into Leydig cell mitochondria. Mol Endocrinol 2005; 19: 540-54.
20. Hauet T, Liu J, Li H, Gazouli M, Culty M, Papadopoulos V. PBR, StAR, and PKA: Partners in cholesterol transport in steroidogenic cells. Endocr Res 2002; 28: 395-401.
21. Liu J, Rone MB, Papadopoulos V. Protein-protein interactions mediate mitochondrial cholesterol transport and steroid biosynthesis. J Biol Chem 2006; 281: 38879-93.
22. Li H, Degenhardt B, Tobin D, Yao Z-x, Tasken K, Papadopoulos V. Identification, localization, and function in steroidogenesis of PAP7: A peripheral-type benzodiazepine receptor-and PKA (RI{alpha})-associated protein. Mol Endocrinol 2001; 15: 2211-28.
23. Papadopoulos V, Baraldi M, Guilarte T, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-9.
24. Besman M, Yanagibashi K, Lee T, Kawamura M, Hall P, Shively J. Identification of des-(Gly-Ile)-endozepine as an effector of corticotropin-dependent adrenal steroidogenesis: stimulation of cholesterol delivery is mediated by the peripheral benzodiazepine receptor. Proc Natl Acad Sci USA 1989; 86: 4897-901.
25. Papadopoulos V, Amri H, Li H, Boujrad N, Vidic B, Garnier M. Targeted disruption of the peripheral-type benzodiazepine receptor gene inhibits steroidogenesis in the R2C Leydig tumor cell line. J Biol Chem 1997; 272: 32129-35.
26. West LA, Horvat RD, Roess DA, Barisas BG, Juengel JL, Niswender GD. Steroidogenic acute regulatory protein and peripheral-type benzodiazepine receptor associate at the mitochondrial membrane. Endocrinology 2001; 142: 502-5.
27. James ML, Fulton RR, Vercoullie J, et al. DPA-714, a new translocator protein-specific ligand: Synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med 2008; 49: 814-22.
28. Campiani G, Nacci V, Fiorini I, et al. Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific peripheral-type benzodiazepine receptor ligands. J Med Chem 1996; 39: 3435-50.
29. Culty M, Silver P, Nakazato A, et al. Peripheral benzodiazepine receptor binding properties and effects on steroid synthesis of two new phenoxyphenyl-acetamide derivatives, DAA1097 and DAA1106. Drug Development Research 2001; 52: 475-84.
30. Trapani G, Franco M, Latrofa A, et al. Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: Synthesis, binding affinity, and in vivo studies. J Med Chem 1999; 42: 3934-41.
31. Trapani G, Laquintana V, Denora N, et al. Structure-activity relationships and effects on neuroactive steroid synthesis in a series of 2-phenylimidazo[1,2-a]pyridineacetamide peripheral benzodiazepine receptors ligands. J Med Chem 2005; 48: 292-305.
32. Romeo E, Cavallaro S, Korneyev A, et al. Stimulation of brain steroidogenesis by 2-aryl-indole-3-acetamide derivatives acting at the mitochondrial diazepam-binding inhibitor receptor complex. J Pharmacol Exp Ther 1993; 267: 462-71.
33. Halestrap A, Doran E, Gillespie J, O'Toole A. Mitochondria and cell death. Biochem Soc Trans 2000; 28: 170-7.
34. Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int 2002; 40: 475-86.
35. Li W, Hardwick MJ, Rosenthal D, Culty M, Papadopoulos V. Peripheral-type benzodiazepine receptor overexpression and knockdown in human breast cancer cells indicate its prominent role in tumor cell proliferation. Biochem Pharmacol 2007; 73: 491-503.
36. Hirsch T, Decaudin D, Susin SA, et al. PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection. Exp Cell Res 1998; 241: 426-34.
37. Pastorino JG, Simbula G, Yamamoto K, Glascott PA, Jr., Rothman RJ, Farber JL. The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition. J Biol Chem 1996; 271: 29792-8.
38. Hans G, Wislet-Gendebien S, Lallemend F, et al. Peripheral benzodiazepine receptor (PBR) ligand cytotoxicity unrelated to PBR expression. Biochem Pharmacol 2005; 69: 819-30.
39. Bono F, Lamarche I, Prabonnaud V, Le FurG, Herbert J. Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities. Biochem Biophys Res Commun 1999; 265: 457-61.
40. Veenman L, Papadopoulos V, Gavish M. Channel-like functions of the 18 kDa translocator protein (TSPO): Regulation of apoptosis and steroidogenesis as part of the host-defence response. Curr Pharm Des 2007; 13: 2385-405.
41. Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010; 9: 971-88.
42. Sutter A, Maaser K, Höpfner M, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cells. Int J Cancer 2002; 102: 318-27.
43. Sänger N, Strohmeier R, Kaufmann M, Kuhl H. Cell cyclerelated expression and ligand binding of peripheral benzodiazepine receptor in human breast cancer cell lines. Eur J Cancer 2000; 36: 2157-63.
44. Maaser K, Hopfner M, Jansen A, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer 2001; 85: 1771-80.
45. Hardwick M, Fertikh D, Culty M, Li H, Vidic B, Papadopoulos V. Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: Correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 1999; 59: 831-42.
46. Ikezaki K, Black KL. Stimulation of cell growth and DNA synthesis by peripheral benzodiazepine. Cancer Lett 1990; 49: 115-20.
47. Sakai M, Ferraz-de-Paula V, Pinheiro ML, et al. Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol 2010; 626: 131-8.
48. Zavala F, Taupin V, Descamps-Latscha B. In vivo treatment with benzodiazepines inhibits murine phagocyte oxidative metabolism and production of interleukin 1, tumor necrosis factor and interleukin-6. J Pharmacol Exp Ther 1990; 255: 442-50.
49. Zavala F, Veber F, Taupin V, Nguyen A, Descamps-Latscha B. A physiological role for the peripheral benzodiazepine receptor on human neutrophils. Ann N Y Acad Sci 1992; 650: 229-33.
50. Waterfield JD, McGeer EG, McGeer PL. The peripheral benzodiazepine receptor ligand PK 11195 inhibits arthritis in the MRL-lpr mouse model. Rheumatology 1999; 38: 1068-73.
51. Klegeris A, McGeer EG, McGeer PL. Inhibitory action of 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide (PK 11195) on some mononuclear phagocyte functions. Biochem Pharmacol 2000; 59: 1305-14.
52. Soustiel JF, Zaaroor M, Vlodavsky E, Veenman L, Weizman A, Gavish M. Neuroprotective effect of Ro5-4864 following brain injury. Exp Neurol 2008; 214: 201-8.
53. Veiga S, Azcoitia I, Garcia-Segura LM. Ro5-4864, a peripheral benzodiazepine receptor ligand, reduces reactive gliosis and protects hippocampal hilar neurons from kainic acid excitotoxicity. J Neurosci Res 2005; 80: 129-37.
54. Veiga S, Carrero P, Pernia S, Azcoitia I, Garcia-Segura L. Translocator protein (18 kDa) is involved in the regulation of reactive gliosis. Glia 2007; 55: 1426-36.
55. Ryu JK, Choi HB, McLarnon JG. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiol Dis 2005; 20: 550-61.
56. Wilms H, Claasen J, Rohl C, Sievers J, Deuschl G, Lucius R. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiol Dis 2003; 14: 417-24.
57. Giatti S, Pesaresi M, Cavaletti G, et al. Neuroprotective effects of a ligand of translocator protein-18kDa (Ro5-4864) in experimental diabetic neuropathy. Neuroscience 2009; 164: 520-9.
58. Ferzaz B, Brault E, Bourliaud G, et al. SSR180575 (7-Chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4Hpyridazino[ 4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J Pharmacol Exp Ther 2002; 301: 1067-78.
59. Rupprecht R, Rammes G, Eser D, et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009; 325: 490-3.
60. Selleri S, Bruni F, Costagli C, et al. 2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands. Bioorg Med Chem 2001; 9: 2661-71.
61. Selleri S, Gratteri P, Costagli C, et al. Insight into 2-phenylpyrazolo[1,5-a]pyrimidin-3-yl acetamides as peripheral benzodiazepine receptor ligands: Synthesis, biological evaluation and 3D-QSAR investigation. Bioorg Med Chem 2005; 13: 4821-34.
62. Reynolds A, Hanani R, Hibbs D, et al. Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO). Bioorg Med Chem Lett 2010; 20: 5799-802.
63. Da Settimo F, Simorini F, Taliani S, et al. Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem 2008; 51: 5789-97.
64. Campiani G, Ramunno A, Fiorini I, et al. Synthesis of new molecular probes for investigation of steroid biosynthesis induced by selective interaction with peripheral type benzodiazepine receptors (PBR). J Med Chem 2002; 45: 4276-81.
65. Farges R, Joseph-Liauzun E, Shire D, Caput D, Le FurG, Ferrara P. Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5-4864. Mol Pharmacol 1994; 46: 1160-7.
66. 3H]PK 11195 to cerebral cortex and peripheral tissues of various species: Species differences and heterogeneity in peripheral benzodiazepine binding sites. J Neurochem 1987; 49: 1407-14.
67. Parola AL, Laird HE. The bovine peripheral-type benzodiazepine receptor: A receptor with low affinity for benzodiazepines. Life Sci 1991; 48: 757-64.
68. Ostuni MA, Péranzi G, Ducroc RA, et al. Distribution, pharmacological characterization and function of the 18 kDa translocator protein in rat small intestine. Biol Cell 2009; 101: 573-86.
69. Delavoie F, Li H, Hardwick M, et al. In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: Functional significance in drug ligand and cholesterol binding. Biochemistry (Mosc) 2003; 42: 4506-19.
70. Anzini M, Cappelli A, Vomero S, et al. Molecular basis of peripheral vs central benzodiazepine receptor selectivity in a new class of peripheral benzodiazepine receptor ligands related to Alpidem. J Med Chem 1996; 39: 4275-84.
71. 3H]PK 11195, by thermodynamic studies. Life Sci 1983; 33: 449-57.
72. Le FurG, Guilloux F, Rufat P, et al. Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3 isoquinolinecarboxamide. II. In vivo studies. Life Sci 1983; 32: 1849-56.
73. Korkhov VM, Sachse C, Short JM, Tate CG. Threedimensional structure of TspO by electron cryomicroscopy of helical crystals. Structure 2010; 18: 677-87.
74. Yeliseev AA, Kaplan S. TspO of rhodobacter sphaeroides. A structural and functional model for the mammalian peripheral benzodiazepine receptor. J Biol Chem 2000; 275: 5657-67.
75. Joseph-Liauzun E, Delmas P, Shire D, Ferrara P. Topological analysis of the peripheral benzodiazepine receptor in yeast mitochondrial membranes supports a fivetransmembrane structure. J Biol Chem 1998; 273: 2146-52.
76. Bernassau J, Reversat J, Ferrara P, Caput D, Le Fur G. A 3D model of the peripheral benzodiazepine receptor and its implication in intra mitochondrial cholesterol transport. J Mol Graph 1993; 11: 236-44.
77. Murail S, Robert J-C, Coïc Y-M, et al. Secondary and tertiary structures of the transmembrane domains of the translocator protein TSPO determined by NMR. Stabilization of the TSPO tertiary fold upon ligand binding. Biochim Biophys Acta 2008; 1778: 1375-81.
78. Papadopoulos V, Boujrad N, Ikonomovic MD, Ferrara P, Vidic B. Topography of the Leydig cell mitochondrial peripheral-type benzodiazepine receptor. Mol Cell Endocrinol 1994; 104: R5-R9.
79. Boujrad N, Vidic B, Papadopoulos V. Acute action of choriogonadotropin on Leydig tumor cells: changes in the topography of the mitochondrial peripheral-type benzodiazepine receptor. Endocrinology 1996; 137: 5727-30.
80. Riond J, Mattei M, Kaghad M, et al. Molecular cloning and chromosomal localization of a human peripheral-type benzodiazepine receptor. Eur J Biochem 1991; 195: 305-11.
81. Anzini M, Cappelli A, Vomero S, et al. Mapping and fitting the peripheral benzodiazepine receptor binding site by carboxamide derivatives. Comparison of different approaches to quantitative ligand-receptor interaction modeling J Med Chem 2001; 44: 1134-50.
82. Benavides J, Begassat F, Phan T, et al. Histidine modification with diethylpyrocarbonate induces a decrease in the binding of an antagonist, PK 11195, but not of an agonist, Ro5-4864, of the peripheral benzodiazepine receptors. Life Sci 1984; 35: 1249-56.
83. 3H]Ro5-4864 in human brain. Eur J Pharmacol 1997; 340: 89-99.
84. Skowronski R, Beaumont K, Fanestil DD. Modification of the peripheral-type benzodiazepine receptor by arachidonate, diethylpyrocarbonate and thiol reagents. Eur J Pharmacol 1987; 143: 305-14.
85. 3H]Ro 5-4864. Mol Pharmacol 1982; 22: 26-32.
86. Sprengel R, Werner P, Seeburg PH, et al. Molecular cloning and expression of cDNA encoding a peripheral-type benzodiazepine receptor. J Biol Chem 1989; 264: 20415-21.
87. Benavides J, Menager J, Burgevin M, et al. Characterization of solubilized peripheral type benzodiazepine binding sites from rat adrenals by using [3H]PK 11195, an isoquinoline carboxamide derivative. Biochem Pharmacol 1985; 34: 167-70.
88. Farges R, Joseph-Liauzun E, Shire D, et al. Molecular basis for the different binding properties of benzodiazepines to human and bovine peripheral-type benzodiazepine receptors. FEBS Lett 1993; 335: 305-8.
89. Garnier M, Dimchev AB, Boujrad N, Price JM, Musto NA, Papadopoulos V. In vitro reconstitution of a functional peripheral-type benzodiazepine receptor from mouse Leydig tumor cells. Mol Pharmacol 1994; 45: 201-11.
90. Jamin N, Neumann J-M, Ostuni MA, et al. Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral-type benzodiazepine receptor. Mol Endocrinol 2005; 19: 588-94.
91. Masonis AET, McCarthy MP. Direct interactions of androgenic/anabolic steroids with the peripheral benzodiazepine receptor in rat brain: Implications for the psychological and physiological manifestations of androgenic/anabolic steroid abuse. J Steroid Biochem Mol Biol 1996; 58: 551-5.
92. Boujrad N, Gaillard JL, Garnier M, Papadopoulos V. Acute action of choriogonadotropin on Leydig tumor cells: induction of a higher affinity benzodiazepine-binding site related to steroid biosynthesis. Endocrinology 1994; 135: 1576-83.
93. Papadopoulos V, Brown AS. Role of the peripheral-type benzodiazepine receptor and the polypeptide diazepam binding inhibitor in steroidogenesis. J Steroid Biochem Mol Biol 1995; 53: 103-10.
94. 11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage 2010; 49: 2924-32.
95. Owen DR, Howell OW, Tang S-P, et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab 2010; 30: 1608-18.
96. 11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage 2008; 39: 1289-98.
97. Costa B, Salvetti A, Rossi L, et al. Peripheral benzodiazepine receptor: Characterization in human T-lymphoma Jurkat cells. Mol Pharmacol 2006; 69: 37-44.
98. Owen DRJ, Gunn RN, Rabiner EA, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med 2011; 52: 24-32.
99. Owen DRJ, Lewis AJM, Reynolds R, et al. Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse 2011; 65: 257-9.
100. Awad M, Gavish M. Peripheral-type benzodiazepine receptors in human cerebral cortex, kidney, and colon. Life Sci 1991; 49: 1155-61.
101. Kita A, Kohayakawa H, Kinoshita T, et al. Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. Br J Pharmacol 2004; 142: 1059-72.
102. 11C-labeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo. J Med Chem 2007; 51: 17-30.
103. 18F-PBR06. J Nucl Med 2009; 50: 1047-53.
104. 18F-labeled ligand for imaging brain peripheral benzodiazepine receptors with PET. J Med Chem 2009; 52: 688-99.
105. 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline. J Nucl Med 2011; 52: 107-14.
106. 18F]Pyrazolo[1,5-a]pyrimidines for the study of the peripheral benzodiazepine receptor using positron emission tomography. J Med Chem 2008; 51: 3700-12.
107. 3H]DAA1106, a novel and selective ligand for peripheral benzodiazepine receptors. Eur J Pharmacol 1999; 371: 197-204.
108. Venneti S, Lopresti BJ, Wang G, et al. A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation. J Neurochem 2007; 102: 2118-31.
109. Venneti S, Wang G, Nguyen J, Wiley C. The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders. J Neuropathol Exp Neurol 2008; 67: 1001-10.
110. Roberts JC, Friel SL, Roman S, et al. Autoradiographical imaging of PPAR[gamma] agonist effects on PBR/TSPO binding in TASTPM mice. Exp Neurol 2009; 216: 459-70.